Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine + ECT in Treatment-Resistant MDD
NCT07088380Phase 3Recruiting
- Sponsor
- Vita-Salute San Raffaele University
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Ketamine with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07088380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088380.